July 11 (Reuters) - Briacell Therapeutics Corp BCT.TO:
BRIACELL’S BRIA-IMT™ DEMONSTRATES SURVIVAL ADVANTAGE OVER TRODELVY® AND CONTROL GROUP IN METASTATIC BREAST CANCER
BRIACELL THERAPEUTICS CORP - NO TREATMENT-RELATED DISCONTINUATIONS REPORTED FOR BRIACELL'S BRIA-IMT
BRIACELL THERAPEUTICS CORP - ANNOUNCES UPDATED PHASE 2 DATA FOR BRIA-IMT
BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 13.9 MONTHS OS IN TNBC
BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 17.3 MONTHS OS IN HR+ BREAST CANCER
Source text: ID:nGNX4q7xFD
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。